Exploring the role of aldosterone in right ventricular function

Canadian Journal of Cardiology

Volumn 30, Issue 2, 2014, Pages 155-158

  Harrison, Alexis ^a   Wilson, Brent D ^a   Ryan, John J ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; AMBRISENTAN; CREATININE; EPLERENONE; SPIRONOLACTONE;

ALDOSTERONE BLOOD LEVEL; EDITORIAL; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE FUNCTION; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; LUNG VASCULAR RESISTANCE; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTOLIC HEART FAILURE;

ALDOSTERONE; BLOOD PRESSURE; FEMALE; HEART VENTRICLES; HUMANS; HYPERTENSION; MALE; RENIN; RENIN-ANGIOTENSIN SYSTEM; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 84893003809     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.12.025     Document Type: Editorial

References (34)

1. Simpson S.A., Tait J.F., Wettstein A., et al. Isolation from the adrenals of a new crystalline hormone with especially high effectiveness on mineral metabolism [in undetermined language]. Experientia 1953, 9:333-335.
2. Williams J.S., Williams G.H. 50th anniversary of aldosterone. J Clin Endocrinol Metab 2003, 88:2364-2372.
3. Guichard J.L., Clark D., Calhoun D.A., Ahmed M.I. Aldosterone receptor antagonists: current perspectives and therapies. Vasc Health Risk Manag 2013, 9:321-331.
4. Selye H. The general adaptation syndrome and the diseases of adaptation. J Allergy 1946, 17:231. 289, 358.
5. Rossi G.P., Sacchetto A., Visentin P., et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996, 27:1039-1045.
6. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2013, 62:e147-e239.
7. McMurray J.J., Adamopoulos S., Anker S.D., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012, 33:1787-1847.
8. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999, 341:709-717.
9. Pitt B., Williams G., Remme W., et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001, 15:79-87.
10. Zannad F., McMurray J.J., Krum H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011, 364:11-21.
11. Juurlink D.N., Mamdani M.M., Lee D.S., et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004, 351:543-551.
12. Srivastava D., Olson E.N. A genetic blueprint for cardiac development. Nature 2000, 407:221-226.
13. Rich S., Pogoriler J., Husain A.N., et al. Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension. Chest 2010, 138:1234-1239.
14. Schwartz A., Lee K.S. Study of heart mitochondria and glycolytic metabolism in experimentally induced cardiac failure. Circ Res 1962, 10:321-332.
15. Piao L., Fang Y.H., Parikh K.S., et al. Grk2-mediated inhibition of adrenergic and dopaminergic signaling in right ventricular hypertrophy: therapeutic implications in pulmonary hypertension. Circulation 2012, 126:2859-2869.
16. Bristow M.R., Minobe W., Rasmussen R., et al. Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest 1992, 89:803-815.
17. Sabri A., Samuel J.L., Marotte F., et al. Microvasculature in angiotensin II-dependent cardiac hypertrophy in the rat. Hypertension 1998, 32:371-375.
18. Bogaard H.J., Natarajan R., Henderson S.C., et al. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation 2009, 120:1951-1960.
19. de Man F.S., Tu L., Handoko M.L., et al. Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. Am J Respir Crit Care Med 2012, 186:780-789.
20. Maron B.A. Targeting neurohumoral signaling to treat pulmonary hypertension: the right ventricle coming into focus. Circulation 2012, 126:2806-2808.
21. Campo A., Mathai S.C., Le Pavec J., et al. Outcomes of hospitalisation for right heart failure in pulmonary arterial hypertension. Eur Respir J 2011, 38:359-367.
22. Galie N., Hoeper M.M., Humbert M., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009, 34:1219-1263.
23. Maron B.A., Zhang Y.Y., White K., et al. Aldosterone inactivates the endothelin-b receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension. Circulation 2012, 126:963-974.
24. Maron B.A., Waxman A.B., Opotowsky A.R., et al. Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials). Am J Cardiol 2013, 112:720-725.
25. Gregori M., Tocci G., Giammariolo B., et al. Abnormal regulation of renin angiotensin aldosterone system is associated with right ventricular dysfunction in hypertension. Can J Cardiol 2014, 30:188-194.
26. Gregori M., Tocci G., Marra A., et al. Inadequate RAAS suppression is associated with excessive left ventricular mass and systo-diastolic dysfunction. Clin Res Cardiol 2013, 102:725-733.
27. McLaughlin V.V., Archer S.L., Badesch D.B., et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation task force on expert consensus documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009, 53:1573-1619.
28. Rudski L.G., Lai W.W., Afilalo J., et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010, 23:685-713. [quiz: 786-8].
29. Packer M. Multicentre, double-blind, placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure-results of the REACH-1 trial (abstract). Circulation 1998, 98(suppl 17):I-3.
30. Redfield M.M., Chen H.H., Borlaug B.A., et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013, 309:1268-1277.
31. Chabot A., Jiang B.H., Shi Y., Tardif J.C., Dupuis J. Role of aldosterone on lung structural remodelling and right ventricular function in congestive heart failure. BMC Cardiovasc Disord 2011, 11:72.
32. Borgdorff M.A., Bartelds B., Dickinson M.G., Steendijk P., Berger R.M. A cornerstone of heart failure treatment is not effective in experimental right ventricular failure. Int J Cardiol 2013, 169:183-189.
33. Edelmann F., Wachter R., Schmidt A.G., et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 2013, 309:781-791.
34. Owan T.E., Hodge D.O., Herges R.M., et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006, 355:251-259.